Open AccessAbstract CT192: Randomized phase II study of canakinumab (CAN) or pembrolizumab (PEM) alone or in combination as neoadjuvant therapy in patients (Pts) with surgically resected (Stage IB-IIIA) non-small cell lung cancer (NSCLC): CANOPY-N
Author(s) -
Jay M. Lee,
P. Garrido,
Edward S. Kim,
Çağatay Arslan,
Jean-Louis Pujol,
Yuanbo Song,
Cecile Blin,
Vanessa Rodrik-Outmezguine,
Bijoyesh Mookerjee,
Vanessa Q. Passos,
T. Mok
Publication year - 2020
Publication title -
cancer research
Language(s) - English
Resource type - Conference proceedings
SCImago Journal Rank - 1.055
H-Index - 84
eISSN - 1538-7445
pISSN - 0008-5472
DOI - 10.1158/1538-7445.am2020-ct192
Subject(s) - medicine , neoadjuvant therapy , oncology , non small cell lung cancer (nsclc) , pembrolizumab , lung cancer , stage (stratigraphy) , placebo , chemotherapy , combination therapy , cancer , gastroenterology , immunotherapy , pathology , breast cancer , paleontology , biology , alternative medicine , a549 cell